Type 2 Diabetes: What to Do When Dual-Combination Therapy Has Not Reached the Glycemic Goal

When type 2 diabetes remains inadequately controlled despite metformin combined with a second glucose-lowering agent, further escalation is indicated to achieve and sustain the individualized glycemic target.

Previous Treatment & Why This Protocol Is Needed

The prior step used metformin plus a second glucose-lowering agent (dual-combination therapy). Despite this, the primary goal was not met: achievement and maintenance of the individualized glycemic goal (A1C below 7%) was not reached. This protocol defines the structured step taken after that failure.

Clinical Goal

Achievement and maintenance of the individualized glycemic goal, with A1C below 7%.

Next-Step Approach — Partial Overview

The evidence-based next step involves adding an agent from a specific class of injectable glucose-lowering therapies. This approach is generally preferred over insulin as the first injectable choice in most individuals at this stage of management.

Full agent selection, starting-dose guidance, and titration steps are available in the complete protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.2337/dc26-S009

In adults with type 2 diabetes without severe hyperglycemia or hyperglycemic crisis, GLP-1–based therapy is preferred to insulin for initial or add-on glucose-lowering therapy (Fig. 9.4).
Consider GLP-1 RA or dual GIP and GLP-1 RA in most individuals prior to insulin.
Many individuals will require dual-combination therapy or a more potent glucose-lowering agent to achieve and maintain their goal A1C level.

View source ↗